Australia markets closed

Alterity Therapeutics Limited (ATH.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.00600.0000 (0.00%)
At close: 04:11PM AEST

Alterity Therapeutics Limited

350 Collins Street
Level 14
Melbourne, VIC 3000
61 3 9349 4906

Full-time employees11

Key executives

NameTitlePayExercisedYear born
Mr. Geoffrey Paul Kempler B.Sc.Co-Founder & Non-Executive Chairman313.3kN/A1955
Dr. David A. Stamler M.D.Chief Executive Officer925.95kN/A1961
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.CFO & Company SecretaryN/AN/A1959
Dr. Rudolph Emile Tanzi Ph.D.Chief Scientific Advisor and Member of Research & Development Advisory BoardN/AN/A1959
Dr. Steven D. TargumChief Medical AdvisorN/AN/AN/A
Dr. Robert ChernyHead of ResearchN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Corporate governance

Alterity Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.